4.7 Review

Gene expression and hypoxia in breast cancer

期刊

GENOME MEDICINE
卷 3, 期 -, 页码 -

出版社

BMC
DOI: 10.1186/gm271

关键词

-

资金

  1. GlaxoSmithKline
  2. Cancer Research UK
  3. Oxford National Institute for Health Research (NIHR) Comprehensive Biomedical Research Center
  4. Breast Cancer Research Foundation
  5. EU
  6. Oxford National Institute for Health Research (NIHR) Experimental Cancer Medicine Center

向作者/读者索取更多资源

Hypoxia is a feature of most solid tumors and is associated with poor prognosis in several cancer types, including breast cancer. The master regulator of the hypoxic response is the Hypoxia-inducible factor 1 alpha (HIF-1 alpha). It is becoming clear that HIF-1 alpha expression alone is not a reliable marker of tumor response to hypoxia, and recent studies have focused on determining gene and microRNA (miRNA) signatures for this complex process. The results of these studies are likely to pave the way towards the development of a robust hypoxia signature for breast and other cancers that will be useful for diagnosis and therapy. In this review, we outline the existing markers of hypoxia and recently identified gene and miRNA expression signatures, and discuss their potential as prognostic and predictive biomarkers. We also highlight how the hypoxia response is being targeted in the development of cancer therapies.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据